Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products that are designed to address unmet medical needs of patients in various therapeutic areas worldwide. The company has market cap of $8.41 billion. The companyÂ’s marketed products include ARISTADA for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis who have walking disability; and BYDUREON (exenatide extended-release for injectable suspension) for the treatment of type 2 diabetes. It currently has negative earnings. It is also developing ALKS 5461 that is in Phase III clinical trials for the treatment of depressive disorder; ALKS 3831, which is in Phase III clinical trials to treat schizophrenia; ALKS 8700, a monomethyl fumarate molecule, which is in Phase III clinical trials to treat multiple sclerosis; ALKS 6428, which is in Phase III clinical trials to help physicians transition patients from physical dependence on opioids; and Aripiprazole lauroxil, an injectable atypical antipsychotic, which has completed a Phase I clinical trials for the treatment of schizophrenia, as well as ALKS 4230, a cell activator that is in Phase I clinical trials for cancer immunotherapy.
Analysts expect First National Financial Corporation (TSE:FN) to report $0.74 EPS on February, 27.They anticipate $0.44 EPS change or 37.29% from last quarter’s $1.18 EPS. T_FN’s profit would be $44.37M giving it 9.63 P/E if the $0.74 EPS is correct. After having $0.96 EPS previously, First National Financial Corporation’s analysts see -22.92% EPS growth. The stock decreased 0.97% or $0.28 during the last trading session, reaching $28.5. About 18,580 shares traded. First National Financial Corporation (TSE:FN) has 0.00% since February 14, 2017 and is . It has underperformed by 16.70% the S&P500.
Ratings analysis reveals 100% of Alkermes’s analysts are positive. Out of 3 Wall Street analysts rating Alkermes, 3 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $70.0 while the high is $70.0. The stock’s average target of $70 is 27.99% above today’s ($54.69) share price. ALKS was included in 3 notes of analysts from October 21, 2016. The firm has “Buy” rating by Jefferies given on Friday, October 21. The firm has “Outperform” rating given on Friday, October 21 by Leerink Swann. JP Morgan upgraded Alkermes plc (NASDAQ:ALKS) on Friday, October 21 to “Overweight” rating.
The stock decreased 1.21% or $0.67 during the last trading session, reaching $54.69. About 1.09 million shares traded or 14.41% up from the average. Alkermes plc (ALKS) has risen 47.50% since February 14, 2017 and is uptrending. It has outperformed by 30.80% the S&P500.
Meditor Group Ltd holds 7.95% of its portfolio in Alkermes plc for 1.03 million shares. Opus Point Partners Management Llc owns 48,244 shares or 2.2% of their US portfolio. Moreover, Roanoke Asset Management Corp Ny has 1.64% invested in the company for 68,621 shares. The California-based Kelly Lawrence W & Associates Inc Ca has invested 1.24% in the stock. Twin Focus Capital Partners Llc, a Massachusetts-based fund reported 40,000 shares.
Analysts await Alkermes plc (NASDAQ:ALKS) to report earnings on February, 21. They expect $-0.01 EPS, up 75.00% or $0.03 from last year’s $-0.04 per share. After $-0.09 actual EPS reported by Alkermes plc for the previous quarter, Wall Street now forecasts -88.89% EPS growth.